In addition, Ganetespib and 17-AAG decreased PD-L1 transcription through destabilizing Hsp90 clients MYC and STAT3 in monocytes and tumor cells at the sub-cytotoxic concentration, and Ganetespib diminished PD-L1 level on MC38 tumor cells in vivo (46). The gene discussed is HSP90AA1; the disease is neoplasm.